FDG PET/CT after first molecular targeted therapy predicts survival of patients with renal cell carcinoma

[1]  Amy M. Sitapati,et al.  NCCN Guidelines Insights: Breast Cancer, Version 1.2017. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[2]  U. Tateishi,et al.  One-month assessment of renal cell carcinoma treated by everolimus using FDG PET/CT predicts progression-free and overall survival , 2017, Cancer Chemotherapy and Pharmacology.

[3]  U. Tateishi,et al.  The acceleration of glucose accumulation in renal cell carcinoma assessed by FDG PET/CT demonstrated acquisition of resistance to tyrosine kinase inhibitor therapy , 2017, BMC Cancer.

[4]  U. Tateishi,et al.  FDG PET/CT as a prognostic biomarker in the era of molecular-targeting therapies: max SUVmax predicts survival of patients with advanced renal cell carcinoma , 2016, BMC Cancer.

[5]  P. Kantoff,et al.  Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[6]  A. Ravaud,et al.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. , 2015, The New England journal of medicine.

[7]  K. Kitajima,et al.  Clinically significant association between the maximum standardized uptake value on 18F-FDG PET and expression of phosphorylated Akt and S6 kinase for prediction of the biological characteristics of renal cell cancer , 2015, BMC Cancer.

[8]  T. Choueiri,et al.  The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. , 2015, The Lancet. Oncology.

[9]  J. Reeves,et al.  Pazopanib versus sunitinib in metastatic renal-cell carcinoma. , 2013, The New England journal of medicine.

[10]  D. Appelbaum,et al.  FDG-PET as a predictive biomarker for therapy with everolimus in metastatic renal cell cancer , 2013, Cancer medicine.

[11]  O. Topolcan,et al.  18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation. , 2013, Anticancer research.

[12]  U. Tateishi,et al.  Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course , 2012, BMC Cancer.

[13]  R. Motzer,et al.  Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial , 2011, The Lancet.

[14]  T. Powles,et al.  Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer , 2011, Clinical Cancer Research.

[15]  U. Tateishi,et al.  Impact of maximum Standardized Uptake Value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report , 2010, BMC Cancer.

[16]  C. Porta,et al.  Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  M. Boijsen,et al.  Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2-deoxyglucose positron emission tomography and computed tomography , 2009, Nuclear medicine communications.

[18]  Jong Wook Park,et al.  Significance of 18F‐fluorodeoxyglucose positron‐emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma , 2009, BJU international.

[19]  E. Hindié,et al.  18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. , 2009, Cancer biotherapy & radiopharmaceuticals.

[20]  R. Motzer,et al.  Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial , 2008, The Lancet.

[21]  David McDermott,et al.  Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. , 2007, The New England journal of medicine.

[22]  W. Rathmell,et al.  Renal cell carcinoma , 2007, Current opinion in oncology.

[23]  Apurva A Desai,et al.  Sorafenib in advanced clear-cell renal-cell carcinoma. , 2007, The New England journal of medicine.

[24]  R. Figlin,et al.  Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.

[25]  H. Sasser,et al.  Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma. , 2004, The Journal of urology.

[26]  T. Olencki,et al.  F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Figlin,et al.  Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. , 2003, The Urologic clinics of North America.

[28]  H. Bensadoun,et al.  Efficiency of [18F]FDG PET in characterising renal cancer and detecting distant metastases: a comparison with CT , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  W. Linehan,et al.  Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. , 1993, Seminars in urology.

[30]  R. Motzer,et al.  Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.